PH12020550550A1 - Sustained-release implants for lowering intraocular pressure with extended duration of effect - Google Patents

Sustained-release implants for lowering intraocular pressure with extended duration of effect

Info

Publication number
PH12020550550A1
PH12020550550A1 PH12020550550A PH12020550550A PH12020550550A1 PH 12020550550 A1 PH12020550550 A1 PH 12020550550A1 PH 12020550550 A PH12020550550 A PH 12020550550A PH 12020550550 A PH12020550550 A PH 12020550550A PH 12020550550 A1 PH12020550550 A1 PH 12020550550A1
Authority
PH
Philippines
Prior art keywords
intraocular pressure
sustained
effect
extended duration
lowering intraocular
Prior art date
Application number
PH12020550550A
Other languages
English (en)
Inventor
Michael R Robinson
Marina Bejanian
Michelle Y Chen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PH12020550550A1 publication Critical patent/PH12020550550A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
PH12020550550A 2017-11-09 2020-05-04 Sustained-release implants for lowering intraocular pressure with extended duration of effect PH12020550550A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US201862683337P 2018-06-11 2018-06-11
PCT/US2018/059910 WO2019094652A1 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Publications (1)

Publication Number Publication Date
PH12020550550A1 true PH12020550550A1 (en) 2021-03-22

Family

ID=64457124

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550550A PH12020550550A1 (en) 2017-11-09 2020-05-04 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Country Status (16)

Country Link
US (2) US20190192341A1 (https=)
EP (1) EP3706717A1 (https=)
JP (2) JP2021502366A (https=)
KR (1) KR20200086289A (https=)
CN (1) CN111315361A (https=)
AU (2) AU2018366214B2 (https=)
BR (1) BR112020009224A2 (https=)
CA (1) CA3080908A1 (https=)
CL (1) CL2020001183A1 (https=)
CO (1) CO2020006924A2 (https=)
IL (1) IL273946A (https=)
MX (2) MX2020004730A (https=)
PH (1) PH12020550550A1 (https=)
RU (1) RU2020113494A (https=)
SG (1) SG11202004126XA (https=)
WO (1) WO2019094652A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3062775T (pt) * 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
WO2022011321A1 (en) 2020-07-10 2022-01-13 Allergan, Inc. Posterior chamber delivery device for sustained release implant
TW202216159A (zh) * 2020-07-21 2022-05-01 美商歐樂根公司 具高負載前列腺素醯胺之眼內植入物
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
PT3062775T (pt) * 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
WO2017015675A1 (en) * 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants

Also Published As

Publication number Publication date
MX2023011426A (es) 2023-10-17
CL2020001183A1 (es) 2020-11-06
MX2020004730A (es) 2020-08-13
KR20200086289A (ko) 2020-07-16
CA3080908A1 (en) 2019-05-16
JP2024032731A (ja) 2024-03-12
SG11202004126XA (en) 2020-06-29
EP3706717A1 (en) 2020-09-16
US20190192341A1 (en) 2019-06-27
AU2018366214B2 (en) 2024-11-14
US20240130890A1 (en) 2024-04-25
US20240225893A9 (en) 2024-07-11
RU2020113494A3 (https=) 2021-12-09
CO2020006924A2 (es) 2020-06-19
AU2024227541A1 (en) 2024-11-14
IL273946A (en) 2020-05-31
JP2021502366A (ja) 2021-01-28
CN111315361A (zh) 2020-06-19
WO2019094652A1 (en) 2019-05-16
RU2020113494A (ru) 2021-12-09
BR112020009224A2 (pt) 2020-10-13
AU2018366214A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2023011426A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
EP4445954A3 (en) Cellular models of and therapies for ocular diseases
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
IL276383A (en) Treatment of ophthalmological diseases
EP4248971A3 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
IL277557A (en) Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
IL287758A (en) Anti-sema3a antibodies and their use for the treatment of eyes or eye diseases
GB2541840A (en) Ophthalmic composition for the treatment of ocular infection
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
ZA202107235B (en) Compositions and methods for treating ocular disease
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
EP3914263A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES AND DISORDERS
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
EA201992210A1 (ru) Предотвращение и/или лечение воспалительного заболевания кожи
ZA202100656B (en) Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
IL291522A (en) Anti-nrp1a antibodies and their uses for the treatment of eyes or eye diseases
EP4257128A3 (en) Methods and compounds for the treatment of genetic disease
MX2019002494A (es) Uso de nootkatona para tratar y prevenir las infestaciones de mosquitos.
WO2015200601A3 (en) Lymphangiogenesis inhibitors for cancer and for graft survival
WO2022104102A3 (en) Materials and methods for treating corneal dysfunction
GB202406561D0 (en) An ocular implant for the treatment of glaucoma
HK40048988A (en) Methods of treating retinal diseases
SG11202103215SA (en) Treatment of myopia and other ocular conditions using singlet oxygen